Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8864931 | 0.81 | CDK1 (0.32) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL5021633 | 0.79 | PARP1 (0.34) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL667794 | 0.74 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL874734 | 0.74 | ADORA2A (0.45) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8843867 | 0.73 | PDE4A (0.38) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL6847248 | 0.72 | PDE4A (0.33) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3237727 | 0.72 | PNP (0.30) | — | |
| SCHEMBL6272726 | 0.72 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL2983845 | 0.71 | PNP (0.34) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL20866 | 0.71 | ATAD2 (0.41) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1267898-A4 | BILE ACID CONTAINING PRODRUGS WITH ENHANCED BIOAVAILABILITY | UNIV MARYLAND (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20030212051-A1 | Bile acid containing prodrugs with enhanced bioavailabilty | UNIVERSITY OF MARYLAND, BALTIMORE | 2003-11-13 | — | — | US | disclosed |
| EP-1267898-A2 | BILE ACID CONTAINING PRODRUGS WITH ENHANCED BIOAVAILABILITY | University of Maryland, Baltimore (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001076531-A2 | BILE ACID CONTAINING PRODRUGS WITH ENHANCED BIOAVAILABILITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212051-A1 | Bile acid containing prodrugs with enhanced bioavailabilty | SLC10A2, SLC10A1, NR1H4 | PDE4A 1458/4885PDE4B 1510/4885PDE4C 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.